Back to search

Article

Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study

2024-03-16

Abstract excerpt

<h4>Introduction</h4> Elexacaftor, Tezacaftor, Ivacaftor (ETI) became available in the UK in August 2020 to treat people with Cystic Fibrosis (CF) aged > 12 years. We report a real-world study of clinical outcomes in young people treated with ETI at our CF centre within the first two years of its availability. <h4>Methods</h4> Participants aged 12-17 were identified within our clinic, with demographic data supplem...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
147e9d32-b08b-5780-bdfe-99a5c1493aaa
DOI
10.1101/2024.03.15.24304343
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal studyDOI 10.1101/2024.03.15.24304343
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.Semantic proximity
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.Semantic proximity
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity
Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity
Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity
Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity
A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity
Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosis.Semantic proximity
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals.Semantic proximity
Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele.Semantic proximity
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity
Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.Semantic proximity
Select a neighboring publication to make it the new centre.